Echosens Appoints Romain Baujard as Group Chief Executive Officer

Echosens Appoints Romain Baujard as Group Chief Executive Officer

PARIS, April 28, 2026 /PRNewswire/ -- Echosens, a global diagnostic company specializing in non-invasive medical devices for liver health assessment, has announced the appointment of Romain Baujard as the new Group Chief Executive Officer. This strategic move comes in the wake of the retirement of former CEO Dominique Legros, who has been instrumental in steering the company towards innovation and growth in the hepatology space. With Baujard at the helm, Echosens aims to accelerate its mission to make liver health a vital sign in cardiometabolic care, a crucial step in enhancing patient outcomes worldwide.

Transitioning Leadership

Baujard brings over two decades of experience in the healthcare sector, having held various leadership roles in both established companies and startups. His expertise in strategic development, operational management, and market expansion will be pivotal in driving Echosens' ambitious goals. “I am honored to take on this role at such a pivotal time for Echosens and the liver health community. Our goal is to ensure that liver health becomes a standard measurement in cardiometabolic assessments, which will ultimately lead to earlier interventions and better patient management,” Baujard stated during his appointment announcement.

Focus on Liver Health

The importance of liver health cannot be overstated, especially considering the rising prevalence of liver diseases, including non-alcoholic fatty liver disease (NAFLD) and liver fibrosis. Echosens has been at the forefront of developing technologies that aid in the non-invasive assessment of liver conditions, ensuring that patients receive accurate diagnoses without the need for invasive procedures. Under Baujard's leadership, the company plans to ramp up its research and development efforts to enhance its product offerings and expand its reach into new markets.

Commitment to Innovation

Innovation has always been a cornerstone of Echosens' strategy. The company is renowned for its flagship product, the FibroScan, which allows healthcare professionals to assess liver stiffness and fat content in a quick and painless manner. With Baujard's appointment, there is a renewed commitment to pushing the boundaries of liver diagnostics. “We will be investing heavily in R&D to ensure our devices remain at the cutting edge of technology,” he added. This commitment is expected to solidify Echosens' position as a leader in the diagnostics field.

Industry Response

The announcement of Baujard's appointment has been met with enthusiasm from industry stakeholders. “Romain’s track record speaks for itself. His vision aligns perfectly with the needs of the market,” said a prominent healthcare analyst. “Echosens is poised for significant growth under his leadership, especially as awareness of liver health continues to rise.” With the increasing global focus on preventative care, Echosens is well-positioned to capitalize on these trends and drive adoption of its non-invasive liver assessments.

Future Prospects

Looking ahead, Echosens is set to expand its collaborations with healthcare providers, academic institutions, and research organizations to enhance the understanding of liver health in relation to overall metabolic health. By integrating liver assessments into routine cardiometabolic evaluations, Echosens aims to create a holistic approach to patient care that could lead to improved health outcomes. The company is also exploring partnerships to facilitate the distribution of its technologies in underserved markets, where access to liver health diagnostics is limited.

Conclusion

Romain Baujard's appointment as Group CEO is a significant milestone for Echosens as it embarks on a new chapter of growth and innovation. With a focus on making liver health a vital sign in cardiometabolic care, the company is well-positioned to lead the charge in transforming how healthcare professionals approach liver diagnostics. As Echosens continues to innovate and expand, the future looks promising not only for the company but also for the millions of patients who will benefit from improved liver health assessments.